about
Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analoguesMaternal antiretroviral therapy for the prevention of mother-to-child transmission of HIV in Malawi: maternal and infant outcomes two years after deliveryThe mutational archive in proviral DNA does not change during 24 months of continuous or intermittent highly active antiretroviral therapy.HCV-HIV coinfected pregnant women: data from a multicentre study in Italy.The impact of HBV or HCV infection in a cohort of HIV-infected pregnant women receiving a nevirapine-based antiretroviral regimen in Malawi.Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens.Full Viral Suppression, Low-Level Viremia, and Quantifiable Plasma HIV-RNA at the End of Pregnancy in HIV-Infected Women on Antiretroviral TreatmentEvolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy.HIV-1 DNA dynamics and variations in HIV-1 DNA protease and reverse transcriptase sequences in multidrug-resistant patients during successful raltegravir-based therapy.Viro-immunological response and emergence of resistance in HIV-infected women receiving combination antiretroviral regimens for the prevention of mother-to-child transmission in Malawi.Seroprevalence of hepatitis B and C viruses among HIV-infected pregnant women in Uganda and Rwanda.HIV-1 coreceptor switch during 2 years of structured treatment interruptions.Hepatitis E virus infection in HIV-infected pregnant women and their children in Malawi.CMV infection in a cohort of HIV-exposed infants born to mothers receiving antiretroviral therapy during pregnancy and breastfeeding.Virological Response and Drug Resistance 1 and 2 Years Post-Partum in HIV-Infected Women Initiated on Life-Long Antiretroviral Therapy in Malawi.Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi.Hepatitis B virus mother-to-child transmission among HIV-infected women receiving lamivudine-containing antiretroviral regimens during pregnancy and breastfeeding.Interindividual and intra-individual variabilities of darunavir and ritonavir plasma trough concentrations in multidrug experienced HIV patients receiving salvage regimens.Nonnucleoside reverse transcriptase inhibitor concentrations during treatment interruptions and the emergence of resistance: a substudy of the ISS-PART Trial.Hodgkin's disease in HIV-infected patients: report of eight cases usefully treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) plus granulocyte colony- stimulating factor.Tumor necrosis factor-alpha, Interleukin-10, and alpha-defensins in plasma and breast milk of HIV-infected highly active antiretroviral therapy-treated and untreated pregnant women in Mozambique.Microbial translocation is associated with residual viral replication in HAART-treated HIV+ subjects with <50copies/ml HIV-1 RNA.Cytomegalovirus (CMV) DNA load in breast milk of human immunodeficiency virus-positive women and infant CMV infection acquisition are not reduced with long-term antiretroviral therapy.Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of mother-to-infant transmission in Malawi.Modifications of HIV-1 DNA and provirus-infected cells during 24 months of intermittent highly active antiretroviral therapy.Modifications of residual viraemia in human immunodeficiency virus-1-infected subjects undergoing repeated highly active antiretroviral therapy interruptions.Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens.Antiretroviral prophylaxis for breastfeeding transmission in Malawi: drug concentrations, virological efficacy and safety.Comparison of HIV type 1 sequences from plasma, cell-free breast milk, and cell-associated breast milk viral populations in treated and untreated women in Mozambique.A randomized trial comparing the introduction of ritonavir or indinavir in 1251 nucleoside-experienced patients with advanced HIV infection.Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity.Correlation between HIV-1 viral load quantification in plasma, dried blood spots, and dried plasma spots using the Roche COBAS Taqman assay.Resistance mutation patterns in plasma and breast milk of HIV-infected women receiving highly-active antiretroviral therapy for mother-to-child transmission preventionTriple Antiretroviral Prophylaxis Administered During Pregnancy and After Delivery Significantly Reduces Breast Milk Viral LoadEarly immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volumeDeterminants of Virologic and Immunologic Outcome in Chronically HIV-Infected Subjects Undergoing Repeated Treatment InterruptionsHIV-related morbidity and mortality in patients starting protease inhibitors in very advanced HIV disease (CD4 count of < 50 cells/uL): an analysis of 338 clinical events from a randomized clinical trial*Plasma HIV-1 copy number and in vitro infectivity of plasma prior to and during combination antiretroviral treatment1Quality of life outcomes of combination zidovudine–didanosine–nevirapine and zidovudine–didanosine for antiretroviral-naive advanced HIV-infected patientsQuantification of HIV-RNA from dried blood spots using the Siemens VERSANT(R) HIV-1 RNA (kPCR) assay
P50
Q28344476-6C2BAA77-8D60-4C80-960F-05BF8950DE5CQ28534751-122DB6B4-6C5C-4995-BC92-CDC65D76C480Q30863784-B8A72A02-92BF-41A4-AACC-5B59CBBB62BBQ31011972-B67EF2D0-ECA3-414E-89EF-1C59C11FC7F5Q34523530-C9EEB2A8-BA56-4C49-B56C-6AFFDF6DC575Q34869426-E9CDDFE3-599C-489C-9340-206EDD1993DCQ35861475-15D6B6B1-DF65-4551-AD7F-9387B43254F5Q35953203-D04E7197-92EF-465B-B175-EA8051C43AC0Q38380240-7EC00E08-CA1A-4F88-BD2A-4D2F7DBE911AQ38394525-853A7BEB-16B8-42FB-84BD-02082D45E23AQ38877392-00D5338D-D347-476F-899D-387642684038Q38894109-49BE6FDD-5664-4202-AD3F-5125D148E9C5Q40251666-A730F42A-82A6-4ADE-B878-B34CEA394FB6Q40540194-41DA8C3D-3025-49AC-A069-6501712D553DQ40719420-354D8041-DECC-4A23-B19C-4155BCBC8A2DQ40867191-C3D62A5F-1780-41D0-9BAA-AFE5C90262F6Q41760045-71CA02E6-C984-40C8-A057-CE523B209123Q42246779-C86F6D4E-CECC-41A0-B8C8-D0A7595B8234Q43067976-8B44A2DE-3E31-414F-9CC1-FA7544E6AF1AQ44101957-AF948484-BA86-45C9-A586-2CE225D6D31CQ44495122-C60571E3-63D1-48C9-92CB-C421A8C5135BQ45262691-6DDC33E3-7C8E-4BC3-8FAC-5CD6B2E17B92Q45330472-1C78B019-ACA0-4F85-9966-17F30894FF6BQ45355192-01925554-4AF1-435C-AA4E-BB44B8C598D7Q45361974-244D4BCE-D174-4D00-B824-C8699288BAE6Q45388040-F8876B79-DAF7-4286-955C-F4A767AE014EQ45391845-F224A76D-88D9-42BB-A560-5EF0E4A2046FQ46808222-98015857-80C6-4D6C-89B1-6ABF2FADD230Q46813664-DB336F62-EFA2-46DF-AD2B-D228E90C53ADQ53900357-6A139A85-5E60-4FE2-B599-302AB3C0A8F2Q54153452-79AEA04E-5FA9-492C-AA41-1E29EEFA7FD9Q54451501-4261E605-A34B-4EBF-B37F-0A26215E9D23Q57951608-F73E3380-9AF9-4A85-ACDD-AC18F26055A9Q57951616-47E77285-5683-4836-A855-93056364A9C3Q57997617-DF4632EF-3B1C-431D-A6E0-E37ADFBB716CQ58960848-8B96D0ED-74EF-4A1E-A865-32AE3E54F24CQ58960862-516DE3FD-5049-4119-9E15-1942D0FC07CCQ58960867-6CEAC140-65EF-44D1-8C3D-05C4BA8C0542Q58960872-9AE72CAB-A405-4FE6-B947-FE4705F69739Q58960899-B88A3E85-6603-41DE-B5E1-C4E6E67A159F
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Maria F. Pirillo
@ast
Maria F. Pirillo
@en
Maria F. Pirillo
@es
Maria F. Pirillo
@nl
Maria F. Pirillo
@sl
type
label
Maria F. Pirillo
@ast
Maria F. Pirillo
@en
Maria F. Pirillo
@es
Maria F. Pirillo
@nl
Maria F. Pirillo
@sl
prefLabel
Maria F. Pirillo
@ast
Maria F. Pirillo
@en
Maria F. Pirillo
@es
Maria F. Pirillo
@nl
Maria F. Pirillo
@sl
P106
P1153
6603013405
P21
P31
P496
0000-0002-6186-692X